XLH
  XLH Network

Home About XLH Contact PHEX Modeling Advances in XLH knowledge

 

 

 

XLH Research

Peter Rowe is an Associate Professor at the University of Texas. He recently proposed an integrated model linking together the different key actors of the XLH condition : PHEX (the mutated protein of XLH patients), MEPE, FGF23. On his website, he presents a remarkable animated model explaining the biochemical events leading to the symptoms observed in XLH. To my knowledge, this is the more integrated biochemical model explaining our condition. Please click on the following link for animation:MEPE-ASARM model.


Copyright (C) 2005 by Pol Harvengt.

Recombinant Phex protein

Enobia Pharma is developping an ERT (Enzyme Replacement Therapy) using a recombinant soluble form of Phex, the defective protein of XLH patients. 

Read more>>

 

 

Cinacalcet effect on XLH

Kansas City's Children of Mercy Hospital is currently leading a clinical trial to investigate about the potential benefits of the calcimimetic Cinacalcet on children with XLH.

Read more>>

 

 

ED-71

ED-71 from Chugai Pharma is in Phase III trial for osteoporosis in US. Preclinical data inidicates that the compound could be of interest also for XLH.

Read more>>